EUVIMEDOpdag EUVIMED
EUVIMED · CrossrefJournal

Breast Cancer

ISSN 1340-6868 · Springer Science and Business Media LLC

Latest articles

  1. Longitudinal PRO-CTCAE assessment in patients with HR+/HER2 − metastatic breast cancer initiating palbociclib: feasibility and symptom trajectories in a multicenter prospective cohort study

    Takayuki Iwamoto, Yukari Uemura, Takashi Ishikawa, Azusa Jo, Hirohito Seki, Masahiro Kitada, Tsuyoshi Saito, Kimito Yamada, Shintaro Takao, Daisuke Takabatake, Toru Yokota, Yasuo Hozumi, Yuichiro Kikawa, Akimitsu Yamada, Uhi Toh, Hideki Nishimura, Hiroshi Kaise, Kazuhiko Yamagami, Reiki Nishimura, Kazutaka Narui, Hirofumi Mukai, Naruto Taira

    Published: 2026-11-06DOI: 10.1007/s12282-026-01936-2

  2. Breast cancer statistics for Japan in 2022: annual report of the national clinical database-breast cancer registry—clinical implications including chemosensitivity of breast cancer with low estrogen receptor expression

    Masayuki Nagahashi, Hiraku Kumamaru, Naoko Kinukawa, Takayuki Iwamoto, Masahiro Kawashima, Takayuki Kinoshita, Takaaki Konishi, Yasuaki Sagara, Shinsuke Sasada, Shigehira Saji, Naoko Sanuki, Kenta Tanakura, Naoki Niikura, Minoru Miyashita, Masayuki Yoshida, Takanori Ishida, Naruto Taira

    Published: 2025-03DOI: 10.1007/s12282-025-01671-0

Volumes

2026 · 1312025 · 1492024 · 1242023 · 1092022 · 1152021 · 1472020 · 1402019 · 1042018 · 1002017 · 1082016 · 1242015 · 922014 · 1122013 · 592012 · 602011 · 552010 · 582009 · 572008 · 582007 · 742006 · 692005 · 682004 · 692003 · 632002 · 642001 · 592000 · 721999 · 691998 · 661997 · 551996 · 351995 · 211994 · 24

Viden, der passer til dit arbejde.

Fra en gratis start over personlig litteratursøgning til den komplette Research Suite.

Se priser →

Er alle forlagsfuldtekster inkluderet?

Nej. Bibliografiske referencer, abstracts og fuldtekster er forskellige typer indhold. Om en fuldtekst er tilgængelig, afhænger af kilden, Open Access og dine eksisterende licenser. Et EUVIMED-abonnement erstatter ikke yderligere forlagsrettigheder.